Sunovion Pharmaceuticals Inc., of Marlborough, Mass., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co. Ltd., said the FDA accepted for review a supplemental new drug application for the use of Aptiom (eslicarbazepine acetate) as monotherapy treatment of partial-onset seizures.